Skip to content

#心血管代谢

Today 0 items
Oct 15Thu
  1. Nature76

    Artificial intelligence-enabled clinical phenotyping of human brown fat.

    Brown adipose tissue (BAT) presence is linked to lower prevalence of cardiovascular and psychiatric diseases across a cohort of 101,243 patients from a large cancer centre. Machine learning quantification of BAT activity in roughly 8,700 patients showed higher activity, especially in the axillary depot, correlates with lower odds of cardiometabolic diseases and healthier white fat distribution. Angiotensin receptor blocker use associated with BAT presence, and losartan increased brown adipocyte activity and whole-body energy expenditure, supporting drug repurposing to activate BAT in humans.

    Why it matters: AI phenotyping of 101,243 patients links brown fat to reduced cardiometabolic disease and identifies losartan as a candidate BAT activator.

  2. doi.org40

    Physiological Responses to Intermittent Environmental Heat Stress in Mice

    Intermittent heat stress in C57BL/6J mice (30-37°C, 3 h/day, 4 days/week, up to 4 weeks) produced a neuroendocrine stress response with 2-4-fold higher plasma corticosterone, >50% lower epinephrine, and ~10 mmHg lower systolic and diastolic blood pressure. Despite >30% depletion of circulating immune cells, leukocyte rolling and adhesion to vascular endothelium rose more than 3-fold, indicating endothelial activation that precedes cardiovascular dysfunction. Cardiac systolic function, arterial stiffness, plasma lipids, and organ injury markers were largely unaffected.

  3. fda.gov46

    Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter

    Par Health USA is voluntarily recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level after particulate matter identified as cellulose, polystyrene, polyethylene terephthalate, stopper material and possibly stainless steel was detected. The affected lots, distributed nationwide to wholesalers and hospitals between December 30, 2024 and May 5, 2026, carry a risk of pulmonary emboli, blood vessel occlusion and vein wall inflammation. No adverse events have been reported; distributors and hospital pharmacies should stop use and return inventory through Inmar, Inc.

  4. nature.com71

    Artificial intelligence-enabled clinical phenotyping of human brown fat

    AI-enabled quantification of brown adipose tissue (BAT) activity in humans links higher BAT activity to a healthier metabolic profile and lower rates of psychiatric disease. The same approach identified existing pharmacologic agents that could be repurposed to activate BAT in humans. The work provides a scalable way to phenotype BAT and connect it to clinical outcomes and drug targets.

    Why it matters: It shows AI-based BAT phenotyping at scale, linking brown fat to metabolic and psychiatric outcomes and to repurposable drugs.

  5. nature.com81

    Capillary-selective vasodilation through myosin inhibition halts ischaemic cascades

    Myosin inhibition produces vasodilation that is selective for capillaries and halts the cascades that follow ischaemia, as reported in this work on microvascular obstruction. The approach targets the capillary level, where pericyte-mediated constriction has been linked to no-reflow after ischaemia in the brain, heart and kidney. No quantitative outcome data are reported here.

    Why it matters: It addresses capillary-level no-reflow, a mechanism implicated in stroke, myocardial infarction and kidney injury.

  6. nature.com59

    Overlooked brown fat in our bodies linked to wide range of health benefits

    People with active brown fat are less affected by a range of health issues, including type 2 diabetes, depression and anxiety, according to the largest study of its kind, covering more than 100,000 people scanned with PET and CT. An artificial-intelligence model quantified active brown fat from the scans, showing that more active brown fat tracked with greater protection from disorders and diseases. The work, published in Nature, expands the list of benefits linked to brown fat, though causation is not yet shown.

Oct 14Wed
  1. biospace.com48

    Alnylam bulls and bears fight it out after business-shaking guidance cut

    Alnylam cut full-year guidance by about $200 million after second-quarter sales of the TTR silencer Amvuttra in transthyretin-mediated amyloidosis fell short, and its stock has dropped from near $500 to around $250. Analysts at Guggenheim question whether the ATTR-CM opportunity is smaller than expected or whether stabilizers from Pfizer and BridgeBio are becoming preferred, while TD Cowen reiterated a $482 target and BMO argues the cut reflects second-line patient exhaustion. Alnylam is running Phase 3 trials of nucresiran in ATTR-CM and ATTR-PN, and a Phase 3 cardiovascular outcomes trial of zilebesiran in hypertension.

  2. biopharmadive.com56

    Another Paragon spinout goes public through reverse merger

    Alaunos Therapeutics acquired Velaris Therapeutics, Paragon Labs' ninth spinout, in a reverse merger that takes the cardiopulmonary disease drug developer public. Fairmount Funds, which founded Paragon in 2021, led a concurrent private placement of about $350 million, with investors including Venrock, Wellington Management and T. Rowe Price accounts, funding operations into 2029. Four of the combined company's five board directors will come from or be picked by Fairmount, and the business will advance Velaris' programs plus an obesity and metabolic disorder drug from Alaunos.

    Why it matters: Reverse mergers have surged to more than two dozen announced this year, matching IPO counts, and Velaris extends the Paragon-Fairmount model.

  3. jamanetwork.com54

    Updated Stroke Guideline Emphasizes Early, Holistic Intervention

    The American Heart Association and the American Stroke Association issued an updated 2026 stroke rehabilitation guideline. It recommends starting rehabilitation as early as possible after stroke and tailoring it to patients' individual physical, cognitive, language, and emotional needs. Clinicians can use it to shape early, holistic rehabilitation programmes.

    Why it matters: Updated AHA/ASA guideline changes recommended practice for stroke rehabilitation.

  4. biopharmadive.com64

    Roche extends China deal streak with $1B pact for RNAi obesity drug

    Roche licensed an experimental RNA interference obesity medicine targeting ALK7 from China-based Rona Therapeutics, paying $100 million upfront for full ownership and up to just over $1 billion in milestones plus royalties. The drug joins five other experimental obesity medicines in Roche's pipeline. It is Roche's fifth deal with a China-based drugmaker since the end of August and 10th since the beginning of 2025.

Oct 13Tue
  1. biospace.com65

    Roche expands obesity R&D footprint with Rona deal worth $1B+

    Roche has licensed an RNAi-based ALK7 obesity drug candidate from China's Rona Therapeutics, paying up to $100 million upfront and in near-term milestones plus as much as $1.06 billion in future milestones. ALK7 inhibition may reduce fat deposits while preserving muscle, an option GLP-1 drugs lack. The deal follows Roche returning its anti-myostatin therapy emugrobart to subsidiary Chugai after a mid-stage analysis found it unlikely to produce meaningful weight loss.

  2. JAMA68

    Development and Validation of an Adult Medical Urgency Score for US Donor Heart Allocation.

    A continuous medical urgency score for US donor heart allocation, the US Candidate Risk Score (US-CRS), built from 5 laboratory values and 4 therapeutic devices, outperformed the current 6-status system for predicting 6-week waitlist mortality (test-set mean time-dependent AUC 0.807 vs 0.693). In a match-run simulation of 45,530 donor hearts, US-CRS-based allocation moved 67% of transplant recipients down in rank order and raised 6-week transplant-censored mortality for the first-listed candidate from 11.2% to 15.7%, indicating the sickest candidates are prioritized earlier.

    Why it matters: It offers a validated, objective alternative to the current 6-status US donor heart allocation system.

Oct 12Mon
  1. Alzheimers Dement42

    The effects of improved access to diabetes medications on risk of Alzheimer's disease and related dementias.

    A dynamic microsimulation using 10 years of data on Americans aged 51 and older with diabetes estimates that increased utilization of GLP1s and SGLT2s by people with diabetes and HbA1c > 7 could avert 76,000-201,000 cases of Alzheimer's disease and related dementias over 10 years. Risk reduction is largest for Black and Hispanic individuals and those with HbA1c > 8, pointing to access and adherence for high-risk groups as the target with the largest benefit.

  2. Sci Adv57

    ALIX-dependent small extracellular vesicles from tissue-resident mesenchymal cells regulate pancreatic β cell proliferation in obesity.

    Deleting ALIX in PDGFRα+ mesenchymal progenitors of mice blocks small extracellular vesicle production and disrupts metabolism. In high-fat diet-induced obesity, these knockout mice gained less weight and had smaller subcutaneous adipocytes, yet showed impaired glucose tolerance with reduced pancreatic β cell area and smaller islets despite normal insulin sensitivity. Conditioned-media sEVs from knockout mesenchymal stem cells lost the ability to promote β cell proliferation, identifying mesenchymal sEVs as regulators of β cell proliferation in obesity.

    Why it matters: Identifies mesenchymal-cell-derived vesicles as a required signal for pancreatic β cell proliferation in obesity.

Oct 10Sat
  1. Nature80

    Dynamics of human cardiogenesis and its disruption in trisomy 21.

    A spatially resolved single-cell multiomics map of the developing human heart defines 21 tissue niches, resolves three pacemaker cell subtypes in the sinoatrial node, and traces maturation trajectories of atrial and ventricular cardiomyocytes. Trisomy 21 hearts show depletion of compact cardiomyocytes and increased apoptosis relative to euploid hearts, a finding validated in isogenic-matched induced pluripotent stem cell-derived cardiomyocytes, providing a mechanistic lead on congenital heart disease risk in Down's syndrome.

    Why it matters: It links a cellular deficit in trisomy 21 hearts to congenital heart disease risk using a spatial human cardiac development atlas.

Oct 9Fri
  1. biospace.com54

    TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms

    TRexBio raised $116.7 million in its Nasdaq IPO, selling 8.3 million shares at $14 to fund TRB-061, a fusion protein in early-stage development for atopic dermatitis with a Phase 1b topline readout expected mid-2027. Retension Pharmaceuticals raised $45 million at $12 per share to advance RTN-001, a PDE-5 blocker for hypertension, through Phase 2b and into Phase 3. City Therapeutics expects about $158.3 million and Iambic Therapeutics about $135 million from upcoming offerings.

    Why it matters: Four biotech IPOs in one week signal a reopening of the public markets for drug developers.

  2. Nature74

    A gut microbial odd-chain fatty acid alleviates atherosclerosis in mice.

    Pentadecanoic acid (PA, C15:0), an odd-chain fatty acid produced by Bacteroides uniformis and other Bacteroidota, alleviates atherosclerosis in mice. PA supplementation cut atherosclerotic plaque burden by around 50% and improved plasma lipid profiles by inhibiting HMG-CoA reductase, suppressing hepatic cholesterol biosynthesis and promoting LDL cholesterol removal via upregulation of hepatic LDL receptor. PA is markedly depleted in patients with dyslipidaemia.

    Why it matters: Identifies a specific microbiota-derived metabolite with a mechanism and roughly 50% plaque reduction in mice.

  3. Cell77

    Immunoregulatory gene GIMAP6 suppresses lethal atherosclerotic vasculopathy and ischemic heart failure.

    Loss of the immunoregulatory gene Gimap6 in mice causes inflammatory vasculopathy and accelerated atherosclerosis without hyperlipidemia, leading to cardiac ischemia, myocardial infarction, heart failure, and early death. Mechanistically, GIMAP6 loss triggers endothelial barrier failure and a mitochondrial ROS-PPARγ-CD36 lipid-influx cascade that promotes foam-cell formation and IL-6/MCP-1/TNF inflammation. Human hypomorphic GIMAP6 variants, including the African-ancestry-enriched V65I allele, are associated with increased CD36-mediated lipid uptake and early ASCVD.

    Why it matters: Identifies a lipid-independent genetic route to lethal atherosclerosis with a corresponding human risk allele.

  4. biorxiv.org51

    Single-nucleus multi-omics reveals reversible molecular signatures in skeletal muscle of patients with heart failure with preserved ejection fraction

    Single-nucleus multiome profiling of 140 skeletal muscle biopsies from 95 individuals (25 healthy controls, 70 HFpEF patients) maps molecular signatures of skeletal muscle remodeling in HFpEF, including type 1 fiber and pericyte depletion and type 2x fiber enrichment. Paired biopsies from 45 HFpEF patients before and after a supervised diet and exercise intervention show the chromatin accessibility and transcriptional changes were partially reversible. HFpEF-linked chromatin was enriched for heart failure and cardiometabolic GWAS signals.

  5. biocentury.com40

    After cardiovascular misses, developers rethink secondary prevention

    Cardiovascular drug developers are reassessing secondary prevention after a series of late-stage failures across IL-6, Lp(a), and Factor XI targets. The failed mechanisms all had substantial human genetic or biological support, exposing the difficulty of translating genetically validated biology into clinical benefit after decades of disease development. Companies including NewAmsterdam Pharma, Regeneron and Forbion are now under pressure to rethink trial design.

Oct 7Wed
  1. nature.com78

    A gut microbial odd-chain fatty acid alleviates atherosclerosis in mice

    The paper reports that a gut microbial odd-chain fatty acid alleviates atherosclerosis in mice. The work draws on mouse experiments together with human gut metagenomic datasets from atherosclerotic cardiovascular disease and subclinical carotid atherosclerosis cohorts, and includes RNA-seq data and molecular docking against the human HMGCR structure.

    Why it matters: Links a gut microbial metabolite to atherosclerosis outcomes in mice, with human metagenomic support.

  2. nature.com75

    Revealed: how this common gut microbe protects against heart disease

    The gut bacterium Bacteroides uniformis, often depleted in people with heart disease, produces pentadecanoic acid, a molecule that lowers cholesterol and shrinks arterial plaque. In mice engineered to develop atherosclerosis, the compound cut arterial plaque by about half, and live B. uniformis shrank plaques by about one-third while reducing total cholesterol and LDL. The molecule inhibits a liver enzyme in cholesterol production that statins also target, and in more than 200 human donors, lower pentadecanoic acid levels linked to abnormally high blood lipids.

  3. Nat Biotechnol63

    Decoding systemic vascular health and hypertensive disorders in pregnancy through retinal imaging and Visionary AI.

    Visionary AI, a platform combining retinal imaging with graph-based vascular modeling, predicted hypertensive disorders of pregnancy before clinical onset. In a prospective development cohort of 1,267 pregnancies it reached AUC 0.91 and average precision 0.81 for preeclampsia, and a stability-optimized model transferred without retraining to external validation at AUC 0.81 and AP 0.68, outperforming clinical and deep learning benchmarks. The finding positions the maternal retina as a minimally invasive biosensor for first-trimester risk stratification.

    Why it matters: First-trimester preeclampsia prediction from retinal images outperformed clinical and deep learning benchmarks in external validation.

  4. fda.gov40

    Rare Disease Drug Approvals

    FDA's CDER lists recent rare disease drug approvals on its Accelerating Rare Disease Cures Program page. In 2026 alone these include Camzyos for an inherited heart condition in children, Emcitate for MCT8 deficiency, Isembyld for muscle loss in spinal muscular atrophy, and Zanvastro for Alexander Disease, among others. The list spans 2021 to 2026 and links to the underlying FDA news releases.

Oct 5Mon
  1. nature.com54

    Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial

    Once-daily oral safiglipron, a small-molecule GLP-1RA, was non-inferior to dapagliflozin for HbA1c reduction at all tested doses and superior at 90 mg in adults with type 2 diabetes in a randomized, double-blind, active-comparator-controlled phase 3 trial. Safiglipron gave greater improvements in glycemic control, similar modest weight loss, and an acceptable safety profile. It offers an oral alternative in the GLP-1 receptor agonist class.

    Why it matters: Phase 3 data show an oral GLP-1RA matching and at 90 mg beating dapagliflozin on HbA1c.

Oct 2Fri
  1. Nat Med61

    Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.

    Semaglutide's kidney protection in type 2 diabetes and chronic kidney disease may work through reduced vascular resistance and prevention of fibrosis. In a 52-week randomized trial of 106 participants, semaglutide 1 mg weekly lowered renal artery resistive index and stabilized the apparent diffusion coefficient versus placebo, while MRI coprimary outcomes (R2* oxygenation, perfusion, T1 inflammation) were unchanged. Paired biopsies showed pronounced effects on glomerular endothelial cells with fewer nearby immune cells.

  2. N Engl J Med69

    Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

    Once-weekly survodutide, a glucagon receptor-GLP-1 receptor dual agonist, produced mean weight reductions of 8.2% at 3.6 mg and 9.8% at 6.0 mg over 76 weeks in 752 adults with type 2 diabetes and BMI of 27 or more, versus 3.9% with placebo. At least 5% weight loss occurred in 57.6% and 64.5% of the survodutide groups versus 35.1% on placebo, with glycated hemoglobin falling 0.9 and 0.8 percentage points. Gastrointestinal adverse events, mostly mild to moderate, occurred in 72.8% and 77.7% of survodutide recipients.

    Why it matters: Phase 3 data show the dual agonist survodutide beats placebo for weight loss in adults with obesity and type 2 diabetes.

  3. Lancet71

    Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

    Orforglipron, an oral non-peptide GLP-1 receptor agonist, was non-inferior to insulin glargine for four-component major adverse cardiovascular events in 2749 adults with type 2 diabetes at increased cardiovascular risk: MACE-4 occurred in 57 (4·2%) of 1358 orforglipron participants versus 67 (5·0%) of 1343 insulin glargine participants (HR 0·84; 95% CI 0·59-1·20) over a median follow-up of 2 years. Clinically significant or severe hypoglycaemia was less frequent with orforglipron (93, 6·8%) than insulin glargine (260, 19·2%), while gastrointestinal adverse events were more frequent (62·1% vs 14·2%). The results establish cardiovascular safety for a non-peptide GLP-1 receptor agonist, a class not previously studied for this outcome.

    Why it matters: First cardiovascular safety data for an oral non-peptide GLP-1 receptor agonist, a class not previously studied for cardiovascular outcomes.

  4. fda.gov54

    FDA Approves First Heart Valve Designed to Grow with Children

    The FDA approved the Autus Size-Adjustable Valve, developed by Autus Valve Technologies and approved via Edwards Lifesciences, for pediatric patients with congenital pulmonary valve disease. It is the first heart valve that can be expanded after implantation, growing from about 13 millimeters to up to 22 millimeters, and the first U.S.-approved valve with polymeric rather than animal-derived leaflets. Approval rests on a study of 62 pediatric patients at 12 U.S. sites, with no deaths or clot-related complications; longer-term studies are under way.

    Why it matters: First FDA-approved expandable pediatric heart valve may cut repeat open-heart surgeries in children.

  5. nature.com61

    Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial

    A randomized placebo-controlled trial in individuals with type 2 diabetes probed the kidney-protective mechanisms of semaglutide using kidney histology, multiparametric MRI and transcriptomics. The findings indicate how semaglutide acts on the kidney in this population, moving the evidence beyond its established glucose-lowering effect toward direct renal mechanisms.

    Why it matters: Mechanistic trial data on semaglutide's kidney protection in type 2 diabetes using histology, MRI and transcriptomics.

Oct 1Thu
  1. BioCentury66

    Novo gets shot at weekly obesity pill as Hengrui gets another MNC deal

    Novo Nordisk has in-licensed ex-China rights to a once-weekly oral dual agonist of GLP1R and GIPR from Jiangsu Hengrui Pharmaceuticals for $300 million up front, in one of the largest preclinical deals to date. The compound is intended for obesity, a core therapeutic area Novo Nordisk is building out through a series of deals this year. Hengrui continues its run of MNC partnerships.

    Why it matters: Large preclinical licensing deal with $300 million up front strengthens Novo Nordisk's obesity pipeline.

  2. JAMA59

    Permissive Blood Pressure Targets in Pediatric Critical Care: The PRESSURE Randomized Clinical Trial.

    A permissive mean arterial pressure target in hypotensive, invasively ventilated children did not change a composite of 30-day mortality and ventilation duration versus usual care (probabilistic index, 0.52; P = .23), while cutting median norepinephrine-equivalent total dose by 37.5%. The trial randomized 1900 patients across 23 PICUs in 3 countries. Kidney replacement therapy, adverse events and most secondary outcomes were similar, though surviving children left the PICU sooner (median 159 vs 166 hours). Clinicians can accept lower MAP targets and reduce vasoactive exposure without worsening outcomes.

    Why it matters: Large multicenter trial showing lower blood pressure targets in PICUs reduce vasoactive drug dose without harming 30-day outcomes.

  3. JAMA46

    Histologic Features and Clinical Outcomes of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease.

    Lean MASLD is a distinct phenotype with milder histologic disease but similar clinical outcomes to overweight/obese MASLD, according to a retrospective study of 18 326 biopsy-confirmed adults across 41 countries. Lean patients (6.7% by BMI) had less advanced fibrosis (29.3% vs 37.2%) and lower type 2 diabetes prevalence (38.2% vs 48.3%), and lean status was not independently associated with all-cause mortality (aHR, 0.90) or clinical events (aHR, 0.94). Fibrosis stage drove prognosis (advanced fibrosis aHR, 2.10 for mortality; 3.41 for events), and liver stiffness measurement outperformed FIB-4 for detecting advanced fibrosis in lean patients (AUC 0.87 vs 0.76).

  4. N Engl J Med82

    Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.

    Once-weekly retatrutide produced mean body-weight reductions of 17.6%, 23.7%, and 25.0% at 4, 9, and 12 mg over 80 weeks in 2339 adults with obesity without diabetes, versus 3.9% with placebo. In subgroups, WOMAC pain fell 3.5 and 3.6 points at 9 and 12 mg versus 1.9 with placebo in 574 participants with knee osteoarthritis, and apnea-hypopnea events per hour fell 34.3 and 31.7 versus 9.9 in 243 participants with obstructive sleep apnea. The phase 3 results extend triple-receptor agonist efficacy beyond weight to obesity-related pain and sleep outcomes.

    Why it matters: Phase 3 data show retatrutide's weight loss and benefits in knee osteoarthritis pain and obstructive sleep apnea.

  5. Nat Med53

    Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

    Once-daily oral safiglipron reduced HbA1c by 1.20 to 1.45 percentage points versus placebo at 32 weeks in 284 adults with early type 2 diabetes managed with diet and exercise alone (OUTSTAND-1, phase 3). HbA1c below 7.0% was reached by 71.4-77.8% of safiglipron recipients versus 25.0% on placebo, with modest weight loss and mostly mild or moderate gastrointestinal adverse events. It offers an oral GLP-1 receptor agonist option taken without fasting or dietary restrictions.

    Why it matters: Phase 3 evidence that an oral small-molecule GLP-1 receptor agonist matches injectable-class glycemic efficacy.

  6. Lancet73

    Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

    Once-weekly retatrutide produced dose-dependent weight loss in adults with obesity and type 2 diabetes over 80 weeks: mean bodyweight change was -16·8% with 9 mg and -18·8% with 12 mg versus -5·1% with placebo. In the phase 3 TRIUMPH-2 trial of 1152 participants, gastrointestinal adverse events were the most frequent, and discontinuation due to adverse events or death was higher with 9 mg and 12 mg than with placebo. The findings support retatrutide as a treatment option for obesity in people with type 2 diabetes.

    Why it matters: Phase 3 data show triple-agonist retatrutide achieves up to -18·8% bodyweight change in obesity with type 2 diabetes.

  7. fda.gov51

    FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

    The FDA is warning patients and health care professionals about risks from unapproved compounded versions of GLP-1 drugs, including semaglutide and tirzepatide, used for weight loss, because these products are not reviewed for safety, effectiveness or quality. The agency states that retatrutide and cagrilintide cannot be used in compounding under federal law, has warned telehealth companies, API distributors and outsourcing facilities over retatrutide, and set up import alert 66-80 to stop GLP-1 APIs with quality concerns at the border. It also advises discarding multi-dose vials within 28 days of first use and not using injectable GLP-1 drugs that arrive warm.

  8. fda.gov61

    FDA approves first drug to improve functional capacity and symptoms in children with rare inherited heart condition

    The FDA approved Camzyos (mavacamten) as the first treatment to improve functional capacity and symptoms in children with symptomatic obstructive hypertrophic cardiomyopathy, extending approval to pediatric patients weighing at least 30 kg, after adult approval in 2022. Efficacy was supported by the phase 3 SCOUT-HCM trial in 44 patients aged 12-18, where once-daily dosing for 28 weeks significantly reduced the Valsalva LVOT gradient versus placebo. The drug carries a boxed warning for heart failure risk and is available only through the Camzyos REMS program.

    Why it matters: First pediatric approval for symptomatic oHCM, backed by phase 3 data in adolescents.

Sep 30Wed
  1. doi.org54

    Akkermansia muciniphila protects diabetes-associated cognitive decline by enhancing leucine catabolism and suppressing neuronal excessive mitophagy

    Low abundance of Akkermansia muciniphila and high leucine levels drive diabetes-associated cognitive decline in diabetic mice and patients. A. muciniphila catabolizes leucine, and excess leucine activates the TBK1-OPTN pathway, enhancing OPTN binding to LC3 and Ub chains and triggering neuronal excessive mitophagy that accelerates cognitive decline in mice. The work identifies a gut-brain metabolic mechanism and a target for gut-directed therapy of cognitive disorders.

    Why it matters: It links a gut bacterium, a metabolite and a defined neuronal mitophagy pathway in diabetes-associated cognitive decline.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org